Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302911 | 0.86 | POLB (0.45) | ALDH1A1KDM4EMAPTPOLBHSD17B10 | |
| SCHEMBL30408659 | 0.86 | POLB (0.45) | ALDH1A1KDM4EMAPTPOLBHSD17B10 | |
| SCHEMBL28824309 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTPOLB | |
| SCHEMBL1938247 | 0.81 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTPOLBHSD17B10 | |
| SCHEMBL27535325 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTPGRNT5E | |
| SCHEMBL9910017 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTPOLBHSD17B10 | |
| SCHEMBL2631833 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTPOLBHSD17B10 | |
| SCHEMBL28735046 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL29441612 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KDM4EPOLBHSD17B10 | |
| SCHEMBL11213802 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KDM4EPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2184683-A | — | — | None | — | — | JP | disclosed |
| US-20180000640-A1 | EYE TREATMENT | NICHAMIN LOUIS D (US) | 2018-01-04 | — | — | US | disclosed |
| US-9788994-B2 | Eye treatment | NICHAMIN LOUIS D (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160235585-A1 | EYE TREATMENT | NICHAMIN LOUIS D (US) | 2016-08-18 | — | — | US | disclosed |
| US-8865232-B2 | Method for treating ocular Demodex | TISSUETECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865232-B2 | Method for treating ocular Demodex | TISSUETECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865232-B2 | Method for treating ocular Demodex | TISSUETECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130344128-A1 | METHOD FOR TREATING OCULAR DEMODEX | TISSUETECH, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130331768-A1 | EYE TREATMENT | NICHAMIN LOUIS D (US) | 2013-12-12 | — | — | US | disclosed |
| US-8440240-B2 | Method for treating ocular demodex | TISSUETECH, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440240-B2 | Method for treating ocular demodex | TISSUETECH, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012092320-A2 | EYE TREATMENT | NICHAMIN LOUIS D (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120004320-A1 | Method for Treating Ocular Demodex | TissueTech,Inc. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004320-A1 | Method for Treating Ocular Demodex | TissueTech,Inc. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004320-A1 | Method for Treating Ocular Demodex | TissueTech,Inc. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20090214676-A1 | METHOD FOR TREATING OCULAR DEMODEX | TISSUETECH, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214676-A1 | METHOD FOR TREATING OCULAR DEMODEX | TISSUETECH, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214676-A1 | METHOD FOR TREATING OCULAR DEMODEX | TISSUETECH, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2006119174-A1 | METHOD FOR TREATING OCULAR DEMODEX | OCULAR SURFACE CENTER, P.A. (US) | 2006-11-09 | — | — | WO | disclosed |
| JP-H02184683-A | CONSCIOUSNESS LEVEL DEPRESSOR | KAO CORP | 1990-07-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004320-A1 | Method for Treating Ocular Demodex | THRB, LIPE, LRAT | ALDH1A1 206/4885KDM4E 3564/4885MAPT 2219/4885 |
| US-20130344128-A1 | METHOD FOR TREATING OCULAR DEMODEX | THRB, THRA, LIPE | ALDH1A1 165/4885KDM4E 3948/4885MAPT 1731/4885 |
| US-20090214676-A1 | METHOD FOR TREATING OCULAR DEMODEX | THRB, THRA, LIPE | ALDH1A1 217/4885KDM4E 3790/4885MAPT 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.